

Claims

1. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid (CLA) for making a medication for fighting inflammatory diseases.
2. Use according to claim 1, characterised in that said medicament acts against the hypersensitivity of the bronchia.
3. Use according to claim 1, characterised in that said medicament acts against respiratory diseases, particularly against asthma.
4. Use according to claim 1, characterised in that said medicament acts against rheumatic diseases, particularly rheumatic arthritis.
5. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid for the inhibition of the proliferation of human or animal cells, particularly cells of the immune systems involved in immune response.
6. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid for the support of apoptosis of eosinophilic granulocytes.
7. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid for the inhibition of specific cytokine expression.
8. Use according to at least one of claims 1 to 7, characterised in that a technical grade CLA is used, comprising said *cis*-9,*trans*-11 isomer in amounts of at least 30 % b.w. – calculated on the total CLA content.
9. Use according to at least one of claims 1 to 8, characterised in that a technical grade CLA is used whose acyl moiety comprises at most 30 % b.w. *trans*-10,*cis*-12 isomers and in total less than 1 % b.w. 8,10-, 11,13 and *trans,trans* isomers – calculated on the total CLA content.
10. Use according to at least one of claims 1 to 9, characterised in that said CLA or, as an alternative, said medicament is applied sub-cutaneously, intramuscularly, per inhalation, *per infusionem*, topically or orally.

11. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acids as a nutrition, functional food or dietary supplement agent.

5 12. Use according to at least one of claims 1 to 11, characterised in that said CLA is applied in amounts of from 0.05 to 5 g/day.